Blueprint Medicines to develop novel therapeutics targeting immunokinases
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
List view / Grid view
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
15 March 2016 | By Victoria White
Their work could help unravel how and why people develop Parkinson’s, and aid in the search for potential treatments...
15 March 2016 | By Victoria White
Outpost Medicine is a biopharmaceutical company focused on the development of new treatments of urologic and gynaecologic diseases and disorders...
14 March 2016 | By Victoria White
After three weeks' treatment with HXR9, human mesothelioma tumours in mice stopped growing, with a complete loss of tumour blood vessels and widespread cancer cell death...
14 March 2016 | By Victoria White
Dr Weiner was co-founder with J. Joseph Kim, Ph.D., Inovio’s CEO, of VGX Pharmaceuticals in 2000; via merger VGX later became Inovio Pharmaceuticals...
14 March 2016 | By Victoria White
Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, has appointed Dr Geoff Smith as CEO...
13 March 2016 | By Victoria White
A group of researchers has taken a step toward a male contraceptive pill by tweaking some experimental compounds that show promise...
11 March 2016 | By Victoria White
Scancell is to collaborate with the Karolinska Institutet to explore the scientific and clinical role of citrullinated proteins in the treatment of cancer...
11 March 2016 | By Victoria White
Trioxacarcins disrupt the replication of cancer cells by binding and chemically modifying their genetic material...
10 March 2016 | By Victoria White
Scientists are a step closer to creating blood stem cells that could reduce the need for bone marrow transplants in patients with cancer or blood disorders...
10 March 2016 | By
This graphic depicts a new inhibitor, 6S, locking up an enzyme (red) to block the production of hydrogen sulfide (yellow and white). Hydrogen sulfide concentrations have been shown to climb after the onset of a stroke, leaving to brain damage. CREDIT: Matthew Beio, University of Nebraska-Lincoln Researchers have developed a…
10 March 2016 | By Victoria White
The discovery, made by scientists at The Scripps Research Institute, may provide a target for new therapies for bipolar disorder...
10 March 2016 | By Victoria White
These findings from a new study suggest that psaptides could serve as a promising template for the development of treatment options directed against ovarian and maybe other cancers...
10 March 2016 | By Victoria White
Researchers have identified a first step in the design of a new generation of anti-cancer drugs that include an agent to inhibit resistance to their effectiveness...
10 March 2016 | By Victoria White
PhoreMost has entered into an alliance with The Wistar Institute to identify and de-orphan novel targets in cancer, aging and the immune system...